Acute myocardial infarction associated with Yasmin oral contraceptive [2]

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 3, 2007, Pages 336-337

  Ortí, Guillermo ^a   Mira, Yolanda ^a   Vaya, Amparo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; CARDIOLIPIN ANTIBODY; DROSPIRENONE PLUS ETHINYLESTRADIOL; HOMOCYSTEINE; PROTEIN C; PROTEIN S; TENECTEPLASE;

ACUTE HEART INFARCTION; ADULT; ARTERIOGRAPHY; CASE REPORT; CIGARETTE SMOKING; CORONARY ARTERY OBSTRUCTION; ELECTROCARDIOGRAPHY; FAMILY HISTORY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LETTER; MUTATION; NUCLEAR MAGNETIC RESONANCE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THORAX PAIN;

ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PROGESTERONE CONGENERS; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 34347205213     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607302445     Document Type: Letter

References (12)

1. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ. 1968 ; 2: 199-205.
2. Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ. 2002 ; 324: 869.
3. Inman Whw, Vessey MP, WesterholmB., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ. 1970 ; 2: 203-209.
4. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004 ; 27: 1001-1018.
5. Shulman LP, Goldzieher JW The truth about oral contraceptives and venous thromboembolism. J Reprod Med. 2003 ; 48 (11 suppl). 930-938.
6. Vaya A., Mira Y., Ferrando F., Aznar J. Transient ischaemic attack associated with the new contraceptive Yasmin. Thrombosis Res. 2003 ; 112: 21.
7. Mira Y., Morata C., Vaya A., Contreras T., Aznar J. Is Yasmin as safe as other contraceptive pills? Clin Appl Thromb Hemost. 2006 ; 12: 378-379.
8. van Grootheest K., Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ. 2003 ; 326: 257.
9. Vaya A., Mira Y., Ferrando F., et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol. 2002 ; 118: 255-259.
10. Doggen CJ, Smith NL, Lemaitre RN Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004 ; 24: 1970-1975.
11. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod. 2002 ; 17: 2307-2314.
12. Kluft C., Lansink M. Effect of oral contraceptives on hemostatic variables. Thromb Haemostasis. 1997 ; 78: 315-326.